Abstract
Intradetrusor injection of botulinum toxin A (BTX-A) is an effective option for managing patients with neurogenic detrusor overactivity (NDO) who do not respond to or tolerate oral pharmacologic agents. There is level I evidence that intradetrusor injection of onabotulinumtoxinA for refractory NDO in patients with multiple sclerosis and spinal cord injury is associated with a significantly greater achievement of goals and improved performance in urodynamic studies than placebo. Pilot studies or small case series support BTX-A for NDO in patients with Parkinson's disease and cerebrovascular accident. BTX-A seems to be effective in children with myelomeningocele. However, no adult data exists.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 463-474 |
| Number of pages | 12 |
| Journal | Urologic Clinics of North America |
| Volume | 44 |
| Issue number | 3 |
| DOIs | |
| State | Published - Aug 2017 |
Keywords
- Botulinum toxin
- Detrusor overactivity
- Multiple sclerosis
- Myelomeningocele
- Neurogenic
- Overactive bladder
- Parkinson's disease
- Urinary incontinence
ASJC Scopus subject areas
- Urology
Fingerprint
Dive into the research topics of 'Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS